S&P Futures
5,893.00 -3.25 (-0.06%) Dow Futures
43,137.00 -40.00 (-0.09%) Nasdaq Futures
20,499.50 -20.00 (-0.10%) Russell 2000 Futures
2,250.70 -4.80 (-0.21%) Crude Oil
70.54 -0.02 (-0.03%) Gold
2,736.50 -2.40 (-0.09%)
Bright Minds Biosciences Inc. (DRUG)
After hours:
| Previous Close | 47.21 |
| Open | 58.10 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 44.72 - 62.99 |
| 52 Week Range | 0.93 - 79.02 |
| Volume | |
| Avg. Volume | 2,715,057 |
| Market Cap | 338.042M |
| Beta (5Y Monthly) | 1.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.64 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireBright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (Bright Minds or the Company) (NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric disorders, today announced that it is once again collaborating with Firefly Neuroscience, Inc. (Firefly) (NASDAQ: AIFF), an Artificial Intelligence (AI) company developing innovative solutions that improve brain health outcomes for patients with ne
- GlobeNewswire
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER, British Columbia, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) is pleased to announce a non-brokered private placement of common shares in the capital of the Company (“Shares”) at a price of USD$21.70 per Share (the “Share Offeri
